about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Fresh out of be­lea­guered Mer­ri­mack, Richard Pe­ters jumps in­to the wel­come arms of Tony Coles at Yu­man­i­ty

6 years ago
People

Open­ing new bat­tle­front with Gilead, GSK touts new Dova­to non-in­fe­ri­or­i­ty da­ta months af­ter first ap­proval

6 years ago
R&D

In a first, HKEX re­ceives IPO pitch from lo­cal biotech look­ing to make it big in crowd­ed an­ti­bod­ies field

6 years ago
Financing
China

Trade ten­sions are im­ped­ing the flow of Chi­nese mon­ey to US biotechs — but how much?

6 years ago
Financing
China

IGM Bio­sciences banks a $103M megaround on its quest to pi­o­neer a new kind of can­cer-fight­ing an­ti­body

6 years ago
Financing

Medicxi, Tai­ho in­fuse €30M in­to Evotec spin­out — eye­ing can­cer meds tar­get­ing DNA dam­age re­sponse path­ways

6 years ago
Financing
Startups

Pledg­ing a come­back, Ac­er ax­es pre-com­mer­cial ops, chops staffers in wake of CRL

6 years ago
People

Do ex­ec de­par­tures por­tend clin­i­cal dis­as­ters? An­a­lyst counts the ex­am­ples

6 years ago
R&D

Just how much would no-deal Brex­it harm bio­med­ical sci­ence? Re­searchers speak out

6 years ago
R&D
Discovery

In­cyte flips Chi­na rights of Macro­Gen­ic­s' PD-1 to an am­bi­tious Zai Lab keen on leapfrog­ging pi­o­neers with com­bos

6 years ago
Deals
China

Watch out Ab­b­Vie: Gilead is fast on your heels at the FDA with ri­val JAK in­hibitor fil­go­tinib

6 years ago
R&D
FDA+

In­vestors trapped for an­oth­er 28 days as sus­pen­sion of Wood­ford flag­ship fund drags on

6 years ago
People
Financing

Neil Wood­ford re­fresh­es port­fo­lio with fire sale while in­vestors pon­der fu­ture of sus­pend­ed fund

6 years ago
People
Financing

In an­oth­er shake­up, uBio­me brings in out­side help to re­vamp a mi­cro­bio­me test­ing op­er­a­tion un­der FBI scruti­ny

6 years ago
R&D

Alex­ion's cash cow Soliris just got fat­ter as FDA green­lights an­oth­er block­buster in­di­ca­tion

6 years ago
Pharma

Beef­ing up its new gene ther­a­py unit, Catal­ent inks $18M deal to snap up No­vavax fa­cil­i­ties

6 years ago
Outsourcing
Cell/Gene Tx

Aclaris ham­mered as hair loss drug flops in PhII, days af­ter FDA took is­sue with Es­ka­ta ads

6 years ago
R&D

Vesal­ius gets to work on €120M Fund III — ex­pect more on wom­en's health, on­col­o­gy

6 years ago
Financing

Chris Var­ma un­veils MP­M's lat­est start­up — eye­ing 'un­drug­gable' can­cer tar­gets and pow­ered by ma­chine learn­ing, ...

6 years ago
Financing
Startups

Tasly Bio­phar­ma pitch­es long-await­ed IPO — will it trig­ger an­oth­er $1B gold rush on HKEX?

6 years ago
Financing
China

With 4 more biotech IPOs due to wrap up Q2, how is the class of 2019 far­ing?

6 years ago
Financing

Bet­ter than Am­bi­en? Min­er­va soars on PhI­Ib up­date on sel­torex­ant for in­som­nia

6 years ago
R&D

In $86M IPO pitch, Mirum spells out plans to turn Shire dis­cards in­to or­phan liv­er drug suc­cess­es

6 years ago
Financing

ICER goes af­ter No­var­tis for over­pric­ing MS drug; Val­ne­va, Glax­o­SmithK­line breaks vac­cine pact

6 years ago
News Briefing
First page Previous page 9596979899100101 Next page Last page
A service from the Financial Times